Rigel Pharmaceuticals to buy US rights to Blueprint Medicines’ Gavreto
Blueprint Medicines will be paid a purchase price of $15m, of which $10m is due upon Rigel's first…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Feb 24
Blueprint Medicines will be paid a purchase price of $15m, of which $10m is due upon Rigel's first…
22 Feb 24
A Phase 1 dosage expansion clinical trial combining IO-202 with azacitidine is presently enrolling newly diagnosed CMML patients…
22 Feb 24
The bispecific antibody is intended to connect B-cell maturation antigen on various myeloma cells with CD3-expressing T cells…
20 Feb 24
The fast-track status was based on findings of the previously announced Phase 2 trial that showed a clinically…
19 Feb 24
Under the agreement, Apotex will seek market approval in Canada for VEVYE, IHEEZO, and ZERVIATE in Canada, and…
Patient CarePharmaceuticals and MedicinesPartnerships and Licensing Agreements
19 Feb 24
Amtagvi is a prescription-based tumour-derived autologous T cell immunotherapy and is said to be the first and the…
19 Feb 24
Remsima SC, the first subcutaneous infliximab, now approved in Canada for maintenance therapy in adults with moderately to…
16 Feb 24
The breakthrough therapy status was based on the favourable results of the Phase 2 ENVISION clinical trial in…
14 Feb 24
The US FDA has approved Onivyde plus oxaliplatin, fluorouracil and leucovorin as a potential new standard-of-care first-line of…
14 Feb 24
The FDA has also granted Rare Pediatric Disease Designation for the treatment of Duchenne, Fast Track designation for…